Academic Journal
Treatment sequence of stem cell delivered heterologous oncolytic virus impact on tumor microenvironment in immunocompetent ovarian cancer model.
| Τίτλος: | Treatment sequence of stem cell delivered heterologous oncolytic virus impact on tumor microenvironment in immunocompetent ovarian cancer model. |
|---|---|
| Συγγραφείς: | Abd El-Fattah EE; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Flores L; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Lara J; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Ngai G; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Mooney R; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Aboody K; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Aug 31; Vol. 17, pp. 1898617. Date of Electronic Publication: 2026 Aug 31 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Ovarian Neoplasms*/therapy , Ovarian Neoplasms*/immunology , Ovarian Neoplasms*/pathology , Oncolytic Virotherapy*/methods , Tumor Microenvironment*/immunology , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Mesenchymal Stem Cells*, Vaccinia virus/genetics ; Adenoviridae/genetics ; Dendritic Cells/immunology ; Female ; Animals ; Mice ; Humans ; Mice, Inbred C57BL ; Disease Models, Animal ; Cell Line, Tumor ; Immunocompetence |
| Περίληψη: | Introduction: Ovarian cancer (OC) is a biologically heterogeneous malignancy associated with poor clinical outcomes. Oncolytic viruses (OVs) have emerged as a promising immunotherapeutic strategy; however, optimal approaches to maximize their antitumor efficacy-especially in combinatorial or sequential settings-remain insufficiently defined. To determine how the sequence of administration of two clinically relevant, stem cell-delivered OV platforms influences tumor control and immune remodeling in an immunocompetent OC model. Methods: We investigated the sequence of two clinically relevant products: neural stem cell delivered conditionally replication competent adenovirus (NSC.CRAd-S-pk7; NNV24) and a mesenchymal stem cell delivered vaccinia virus (MSC.VP001; SNV1). Female C57BL/6 mice were randomized into three groups: untreated tumor-bearing controls, NNV24 followed by SNV1 (NNV24+SNV1), or SNV1 followed by NNV24 (SNV1+NNV24). Therapeutic efficacy and immune responses were assessed by overall survival, histopathological evaluation, flow cytometric analysis of dendritic cell (DC) subsets and cytotoxic T lymphocytes (CTLs), and bulk RNA sequencing. Results: Treatment regimens initiated with NNV24 significantly prolonged survival compared with SNV1-first sequences. NNV24+SNV1 treatment resulted in enhanced intratumoral viral localization, increased infiltration of CTLs, mature DCs, and concomitant with a reduction in tolerogenic DC populations. Transcriptomic profiling corroborated these findings through revealing suppression of immunoregulatory and tolerogenic pathways signaling in comparison to SNV1+NNV24 group. Discussion: The treatment sequence of heterologous OV has a significant effect on the tumor microenvironment. NNV24+SNV1 promotes robust antitumor immunity and improved survival, whereas the reverse sequence compromises immune activation and therapeutic response. These findings establish a mechanistic framework for rational sequencing of OV-based immunotherapies. (Copyright © 2026 Abd El-Fattah, Flores, Lara, Ngai, Mooney and Aboody.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Hum Gene Ther. 2007 Jul;18(7):589-602. (PMID: 17630837) J Control Release. 2025 Jul 10;383:113822. (PMID: 40348130) J Transl Med. 2019 Mar 27;17(1):100. (PMID: 30917829) Mol Ther. 2024 Jul 3;32(7):2406-2422. (PMID: 38734899) Front Immunol. 2024 Jan 12;14:1324744. (PMID: 38283361) Cancers (Basel). 2025 Jul 10;17(14):. (PMID: 40723180) Mol Ther. 2011 Sep;19(9):1714-26. (PMID: 21629227) J Am Chem Soc. 2019 Apr 24;141(16):6509-6518. (PMID: 30995022) Int J Cancer. 2022 Nov 15;151(10):1654-1662. (PMID: 35633046) Cancer Gene Ther. 2012 Jun;19(6):431-42. (PMID: 22555507) Oncol Lett. 2021 Apr;21(4):238. (PMID: 33664802) Mol Ther Oncolytics. 2018 Dec 13;12:79-92. (PMID: 30719498) Signal Transduct Target Ther. 2023 Apr 11;8(1):156. (PMID: 37041165) J Pathol. 2012 Jun;227(2):136-45. (PMID: 22322968) JCO Glob Oncol. 2024 May;10:e2300393. (PMID: 38754054) Mol Ther. 2018 Aug 1;26(8):1876-1880. (PMID: 30029891) Mol Ther Oncolytics. 2022 Sep 13;27:3-13. (PMID: 36212775) Cancers (Basel). 2021 Dec 16;13(24):. (PMID: 34944938) Genome Biol. 2014;15(12):550. (PMID: 25516281) PLoS Pathog. 2014 Apr 17;10(4):e1003989. (PMID: 24743339) Vaccine. 2018 Jun 7;36(24):3468-3476. (PMID: 29739720) Stem Cell Res Ther. 2021 Mar 24;12(1):205. (PMID: 33761999) Methods Mol Biol. 2013;1049:425-33. (PMID: 23913235) Signal Transduct Target Ther. 2026 Feb 05;11(1):45. (PMID: 41639062) Stem Cells Transl Med. 2017 Apr;6(4):1120-1131. (PMID: 28205428) Cancer Immunol Immunother. 2024 Nov 5;74(1):12. (PMID: 39499326) Cell Rep Med. 2021 Mar 03;2(3):100209. (PMID: 33763654) J Virol. 2007 Nov;81(22):12102-10. (PMID: 17855554) J Immunother Cancer. 2025 Oct 8;13(10):. (PMID: 41062177) J Cancer Res Clin Oncol. 2025 Aug 2;151(8):225. (PMID: 40751826) Cell Death Dis. 2020 Jan 22;11(1):48. (PMID: 31969562) Oncol Rep. 2021 Apr;45(4):. (PMID: 33760203) Mol Ther. 2018 Aug 1;26(8):1875-1876. (PMID: 30017879) Int J Mol Sci. 2025 Jul 18;26(14):. (PMID: 40725148) Stem Cells Transl Med. 2013 Sep;2(9):655-66. (PMID: 23926209) Cancer Res. 2002 Sep 15;62(18):5260-6. (PMID: 12234994) Lancet Oncol. 2021 Aug;22(8):1103-1114. (PMID: 34214495) Front Immunol. 2022 Jul 07;13:840029. (PMID: 35874739) Curr Protoc Bioinformatics. 2015 Sep 03;51:11.14.1-11.14.19. (PMID: 26334920) Biomark Res. 2021 Jan 6;9(1):1. (PMID: 33407885) Cancers (Basel). 2022 Dec 13;14(24):. (PMID: 36551636) Cancers (Basel). 2025 Jul 12;17(14):. (PMID: 40723208) Int J Oncol. 2009 Mar;34(3):729-42. (PMID: 19212678) PLoS One. 2012;7(9):e45840. (PMID: 23049876) Mol Ther Oncolytics. 2019 Nov 02;15:234-247. (PMID: 31872046) Int J Mol Sci. 2024 Feb 03;25(3):. (PMID: 38339123) |
| Contributed Indexing: | Keywords: adenovirus; immune modulation; oncolytic virotherapy; ovarian cancer; vaccinia virus |
| Entry Date(s): | Date Created: 20260915 Date Completed: 20260915 Latest Revision: 20260916 |
| Update Code: | 20260916 |
| PubMed Central ID: | PMC13572156 |
| DOI: | 10.3389/fimmu.2026.1898617 |
| PMID: | 42741068 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!